Literature DB >> 11282124

Variable responses to prostaglandin E(2) in human non-pregnant myometrium.

A Popat1, D J Crankshaw.   

Abstract

Cumulative concentration-effect curves for prostaglandin E(2), sulprostone and butaprost were constructed in matched strips of human non-pregnant myometrium from 14 different donors. All samples were obtained from the mid-lateral wall of the uterus. Prostaglandin E(2) produced four types of concentration-effect curves: monophasic inhibitory (n = 7), monophasic excitatory (n = 2), biphasic consisting of an excitatory phase followed by an inhibitory phase (n = 4), and biphasic consisting of an inhibitory phase followed by an excitatory phase (n = 1). Sulprostone produced excitation of spontaneous contractile activity in all tissues (mean pEC(50) = 9.1+/-0.2, range 8.1-10.1, n = 14). Butaprost produced relaxation of cloprostenol-stimulated contractile activity in all tissues (mean pEC(50) = 5.7 +/- 0.1, range 5.0-6.9, n = 14). The mean pEC(50) value for sulprostone was significantly higher in tissues where prostaglandin E(2) caused some excitation (pEC(50) = 9.4 +/- 0.2, n = 7) compared to those where prostaglandin E(2) caused only inhibition (pEC(50) = 8.8 +/- 0.2, n = 7). Mean pEC(50) values for butaprost were not significantly different between these groups. These data suggest that (a) variability in EP receptor-mediated responses exists within a single anatomical site; (b) both excitatory and inhibitory EP receptor-mediated pathways are always operative in human non-pregnant myometrium, regardless of the type of tissue response to prostaglandin E(2); and (c) regulation of EP receptor-mediated responses occurs predominantly in the excitatory (EP(3) or EP(1) receptor) pathway rather than the inhibitory (EP(2) receptor) pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11282124     DOI: 10.1016/s0014-2999(01)00852-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  In vitro myometrial contractility profiles of different pharmacological agents used for induction of labor.

Authors:  Giuseppe Chioss; Maged M Costantine; Egle Bytautiene; Ancizar Betancourt; Gary D V Hankins; George R Saade; Monica Longo
Journal:  Am J Perinatol       Date:  2012-05-29       Impact factor: 1.862

2.  On a matter of seminal importance.

Authors:  Lisa A McGraw; Susan S Suarez; Mariana F Wolfner
Journal:  Bioessays       Date:  2014-11-07       Impact factor: 4.345

3.  The effects of prostaglandin E1 and prostaglandin E2 on in vitro myometrial contractility and uterine structure.

Authors:  Giuseppe Chiossi; Maged M Costantine; Egle Bytautiene; Talar Kechichian; Gary D V Hankins; Elena Sbrana; George R Saade; Monica Longo
Journal:  Am J Perinatol       Date:  2012-05-25       Impact factor: 1.862

4.  Heteroactivation of cytochrome P450 1A1 by teas and tea polyphenols.

Authors:  Dana L Anger; Maria-Alexandra Petre; Denis J Crankshaw
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

5.  In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP₂ receptor antagonist.

Authors:  K J af Forselles; J Root; T Clarke; D Davey; K Aughton; K Dack; N Pullen
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

6.  Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development.

Authors:  Sarah Arrowsmith; Peter Keov; Markus Muttenthaler; Christian W Gruber
Journal:  J Vis Exp       Date:  2018-01-26       Impact factor: 1.355

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.